Drug Profile
KSB 301
Alternative Names: CB 2431; KSB301Latest Information Update: 07 Dec 2001
Price :
$50
*
At a glance
- Originator KS Biomedix Holdings
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action Monoamine oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoarthritis
Most Recent Events
- 07 Dec 2001 Discontinued-II for Osteoarthritis in European Union (PO)
- 24 May 2001 KSB 301 is available for licensing (http://www.ksbiomedix.com/)
- 23 May 2001 A phase IIb trial has commenced